Nelociguat is primarily investigated for its potential therapeutic applications in treating cardiovascular diseases. It is a soluble guanylate cyclase (sGC) stimulator, which plays a crucial role in regulating vascular tone and blood pressure. By stimulating sGC, it helps in the relaxation of blood vessels, improving blood flow, and reducing pulmonary hypertension. This makes it a promising candidate for treating conditions like chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Additionally, it is being explored for its potential benefits in heart failure, where improved vascular function can alleviate symptoms and enhance patient outcomes. Research continues to evaluate its efficacy and safety in these clinical settings.